| REGISTERED NUMBER: |
| FINANCIAL STATEMENTS FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| FOR |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED |
| REGISTERED NUMBER: |
| FINANCIAL STATEMENTS FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| FOR |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299) |
| CONTENTS OF THE FINANCIAL STATEMENTS |
| FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| Page |
| Company information | 1 |
| Balance sheet | 2 |
| Notes to the financial statements | 3 |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED |
| COMPANY INFORMATION |
| FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| Directors: |
| Registered office: |
| Registered number: |
| Auditors: |
| Fairway House |
| Links Business Park |
| St Mellons |
| Cardiff |
| CF3 0LT |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299) |
| BALANCE SHEET |
| 31 MARCH 2025 |
| 2025 | 2023 |
| Notes | £ | £ |
| FIXED ASSETS |
| Investments | 4 |
| CURRENT ASSETS |
| Debtors | 5 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 6 | ( |
) | ( |
) |
| NET CURRENT LIABILITIES | ( |
) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
( |
) |
| CAPITAL AND RESERVES |
| Called up share capital |
| Share premium |
| Retained earnings | ( |
) | ( |
) |
| SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299) |
| NOTES TO THE FINANCIAL STATEMENTS |
| FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| 1. | STATUTORY INFORMATION |
| Deciphera Pharmaceuticals (UK) Limited is a |
| The Company's functional and presentational currency is pound sterling (£) and the financial statements have been rounded to the nearest pound (£). |
| The financial statements have been prepared for the period 1 January 2024 to 31 March 2025. The financial accounting period has been extended to align with the fiscal year of its new parent, along with practical considerations regarding the process for implementing that change. As a result the comparative amounts presented are not entirely comparable. |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Going Concern |
| These financial statements have been drawn up on the going concern basis. The company is dependent upon the support of its parent company, in order to meet its working capital requirements. The parent company has provided assurances that this support will continue for a period that exceeds twelve months from the date of approval of these financial statements and believes it will have the funds required to provide this support. |
| On the basis of the assurances received form the parent company the directors believe that the going concern basis is appropriate. No adjustments have been made in these accounts which might result from that uncertainty. |
| Preparation of consolidated financial statements |
| The financial statements contain information about Deciphera Pharmaceuticals (UK) Limited as an individual Company and do not contain consolidated financial information as the parent of a group. The Company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements. |
| Related party exemption |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |
| Turnover |
| Turnover represents amounts charged to the Company's parent under an agreement for marketing and other services provided, excluding value added tax. Turnover is recognised when chargeable costs are incurred. The subcontracting, third-party or foreign exchange costs incurred by the Company in the provision of the services are passed through the Company's parent without applying any mark-up. |
| Investments in subsidiaries |
| Investments in subsidiary undertakings are recognised at cost less any provision for impairment. |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| 2. | ACCOUNTING POLICIES - continued |
| Financial instruments |
| The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments. |
| Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. |
| Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. |
| Classification of financial liabilities |
| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. |
| Basic financial liabilities |
| Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price. |
| Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price. |
| Taxation |
| Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Foreign currencies |
| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the period was |
| DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025 |
| 4. | FIXED ASSET INVESTMENTS |
| Shares in |
| group |
| undertakings |
| £ |
| Cost |
| At 1 January 2024 |
| and 31 March 2025 |
| Net book value |
| At 31 March 2025 |
| At 31 December 2023 |
| 5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2023 |
| £ | £ |
| Other debtors |
| 6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2023 |
| £ | £ |
| Trade creditors |
| Amounts owed to group undertakings |
| Taxation and social security |
| Other creditors |
| 7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006 |
| The Report of the auditors was unqualified. |
| for and on behalf of |
| 8. | ULTIMATE PARENT COMPANY |
| The immediate parent undertaking of the company is Deciphera Pharmaceuticals (Netherlands) B.V., (incorporated in Netherlands) |
| Ono Pharmaceutical Co., Ltd (incorporated in Japan) is regarded by the directors as being the company's ultimate parent company. |
| The largest and smallest group in which the results of the company are consolidated is headed by Ono Pharmaceutical Co., Ltd, incorporated in Japan. Consolidated financial statements for Ono Pharmaceutical Co., Ltd, are available on the company website www.ono-pharma.com. |